Dr Christophe Delehedde
Dr. Christophe Delehedde completed his PhD in the laboratory of Prof. Pichon at the University of Orléans, where he focused on the development of mRNA lipid nanoparticles.
He then joined Sanofi’s mRNA Center of Excellence, playing a key role in the advancement of high-throughput screening of LNP formulations for next-generation vaccine development. Currently at Sanofi Drug Discovery, his research centers on the design and characterization of targeted lipid nanoparticles aimed at precise immune cell engagement. His work paves the way for a broad spectrum of therapeutic applications across the mRNA landscape.
Explore other speakers:
Dr César López-Camacho
The Jenner Institute, University of Oxford
Dr López-Camacho joined Oxford over a decade ago and his research centres on vaccine development against arthropod-borne pathogens spanning viruses transmitted by mosquitoes, ticks, and other vectors.
Dan Peer
Professor and Director, Laboratory of Precision NanoMedicine, Tel Aviv University (TAU)
Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the Vice President for Research and Development in Tel Aviv University. Since 2017, he has been the Founder and Managing Director of the SPARK program, Center for Translational Medicine at TAU.
Dr Daragh Mcloughlin
Principal Scientist, Centre for Process Innovation (CPI)
Daragh specialises in formulation and delivery technologies, with a strong focus on lipid nanoparticle (LNP) systems and microfluidic manufacturing.
Dr Diego de Miguel
Manager of the Formulation Department, Certest Pharma
Dr. Diego de Miguel leads the Lipid Nanoparticle (LNP) Formulation Department at Certest Pharma, where he designs next-generation LNP platforms that broaden the therapeutic potential of mRNA vaccines and other nucleic-acid medicines.
Dr Bakul Gupta
CEO and Co-Founder, Deliver Bio
Dr Bakul Gupta is the CEO and Co-Founder of Deliver Biosciences, a preclinical stage biotech developing nanoparticle-based gene delivery vectors for in vivo cell reprogramming and gene editing.
Erdinc Sezgin, PhD
Professor, Karolinska Institute
Since 2020, Erdinc has been leading his independent lab as an Associate Professor at Karolinska Institutet and SciLifeLab. He is currently an EMBO Young Investigator and a Visiting Faculty at University of Oxford.
Dr Fred Campbell
CEO, Outfox Bio
At Outfox Bio Fred's commitment is not only to develop cheaper, safer and more effective LNP-based gene delivery systems but crucially to ensure a clear and viable route to patients so as to maximize the impact of the coming gene therapy revolution
Dr Heinrich Haas
CTO, Neovac Ltd
Heinrich focuses on advanced approaches for nanoparticle development and control.
Justin R Martin, PhD
Lead Development Scientist, Croda Pharma
Justin spearheads the development and scale-up of lipid production processes under GMP (compliant) conditions.
Michael Hai Luu Nguyen, PhD
VP of Business Development, Helix Biotech
At Helix Biotech, Michael is now applying his skills to help advance RNA and lipid nanoparticle technologies for therapeutic delivery.
Professor Neill Liptrott
Chair of Pharmacology and Immunocompatibility, The University of Liverpool
Neil's research explores immune interactions with complex medicines, biotherapeutics and biomaterials.
Dr Patrícia Monteiro
Senior Scientist, AstraZeneca
Patrícia's work spans from formulation of small molecules to the development of delivery systems for in vivo CAR-T cell generation, with a strong focus on the design, development, and optimisation of targeted lipid nanoparticles (tLNPs).
JunProf. Dr. Philipp Uhl
Group Leader, Lipoid-endowed Professorship, Heidelberg University, Institute of Pharmacy and Molecular Biotechnology
In Philipp's research, he primarily focuses on the development of optimized antibiotics formulations as well as on delivery systems for oral delivery of macromolecular drugs in general.
Professor Avi Schroeder
Professor of Chemical Engineering, Technion–Israel Institute of Technology
Avi is the recipient of more than 40 national and international recognitions, including being named a Fellow of the Royal Society of Chemistry, a KAVLI Fellow, and being awarded the Intel Nanotechnology Award, the TEVA Pharmaceuticals Award, and the Wolf Foundation Krill Award.
Dr Richard A. Campbell
Senior Lecturer in Physical Pharmacy, University of Manchester
Richard has expertise in resolving complex soft matter interactions at fluid interfaces through combined and novel applications of neutron and optical reflectometry.
Professor Robin Shattock
Professor of Mucosal Infection and Immunity, Imperial College
Robin Shattock is Professor of Mucosal Infection and Immunity at Imperial College, London with over 30 years’ experience in research and development of vaccines and anti-infectives.
Tim Leaver
Senior Director Nanomedicine Services and Lipids, Cytiva
At Cytiva, Tim's focus is to bring together a full suite of technologies, services and subject matter experts to ensure we can make every scientist a genomic developer.
Professor Yvonne Perrie
Head of Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde
Yvonne's research focuses on developing drug and vaccine delivery systems to address real-world healthcare challenges